Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: As continuous intraperitoneal insulin infusion (CIPII) results in a more physiologic action of insulin than subcutaneous (SC) insulin administration, we hypothesized that CIPII would result in less glycemic variability (GV) than SC insulin therapy among type 1 diabetes mellitus (T1DM) patients. MATERIALS AND METHODS: Data from 5-day blind continuous glucose monitoring (CGM) measurements performed during a 26-week, prospective, observational case-control study were analyzed. The coefficient of variation (CV) was the primary measure of GV. In addition, the SD of the mean glucose level, mean of daily differences, and mean amplitude of glycemic excursions were calculated. RESULTS: In total, 176 patients (36% male; mean age, 49 [SD 13] years; median diabetes duration, 24 [interquartile range, 17, 35] years; glycated hemoglobin level, 63 [10] mmol/mmol), of which 37 used CIPII and 139 SC insulin therapy, were analyzed. CGM data were available for 169 patients at baseline (CIPII, n=35; SC, n=134) and for 164 patients at 26 weeks (CIPII, n=35; SC, n=129). After adjustment for baseline differences, the CV was 4.9% (95% confidence interval, 1.0, 8.8) lower with CIPII- compared with SC-treated patients, irrespective of the use of multiple daily injections or continuous SC insulin infusion. There were no differences in other indices of GV between groups. CONCLUSIONS: Despite higher blood glucose, the CV was slightly lower with CIPII compared with SC insulin therapy in T1DM patients, and other measures of GV were identical. Future studies are needed to confirm these findings and investigate whether this results in prevention of hypoglycemia and even perhaps (less) microvascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409 · cited 1×
“12,13,35,36 Nevertheless, as current closed-loop systems using SC insulin therapy struggle to reach postprandial normoglycemia, the effects of IP insulin on GV may be of importance for the question of which route of insulin administration is the best for development for a closed-loop system.”
Self-citationCox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. H., Schlundt, D. G., & Clarke, W. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989471 · Cited by 137 · cited 2×
“12,13,35,36 Nevertheless, as current closed-loop systems using SC insulin therapy struggle to reach postprandial normoglycemia, the effects of IP insulin on GV may be of importance for the question of which route of insulin administration is the best for development for a closed-loop system.”
Implantable insulin pumps. A position statement about their clinical use
Renard, E., & Schaepelynck-Bélicar, P. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.10.004 · Cited by 69
Cited by
Glucose Variability: A Review of Clinical Applications and Research Developments
Rodbard, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0092 · Cited by 154
Dassau, E., Renard, E., Place, J., Farret, A., Pelletier, M., Lee, J., Huyett, L. M., Chakrabarty, A., Doyle, F. J., & Zisser, H. C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12999 · Cited by 94
“There is some evidence to show that this difference results in better insulin/glucagon balance and glycaemic variability.(13,14) Some recent studies(15,16) indicate that prolonged use of IP infusion does not adversely affect insulin-like growth-factor-1 (IGF-1) concentrations, as observed with prolonged SC use.”
BackgroundToffanin, C., Magni, L., & Cobelli, C. (2021) · IEEE Transactions on Medical Robotics and Bionics · doi:10.1109/tmrb.2021.3075775 · Cited by 22
Modeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes
Schiavon, M., Cobelli, C., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11090600 · Cited by 6
Metadata
- Authors
- van Dijk, P. R., Groenier, K. H., DeVries, J. H., Gans, R. O. B., Kleefstra, N., Bilo, H. J. G., & Logtenberg, S. J. J.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-06
- Volume
- 17
- Issue
- 6
- Pages
- 379-384
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1959745503
- Cited by
- 19
- References
- 4
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability. https://app.cochat.ai/papers/10.1089/dia.2015.0001
- The paper
- van Dijk, P. R., Groenier, K. H., DeVries, J. H., Gans, R. O. B., Kleefstra, N., Bilo, H. J. G., & Logtenberg, S. J. J. (2015). Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2015.0001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.